Empirical therapy for nonsevere PID
For empirical therapy in nonpregnant patients who do not have features of severe PID, as a 3-drug regimen, useOng, 2023:
ceftriaxone 500 mg intramuscularly or intravenously, as a single dose ceftriaxone ceftriaxone ceftriaxone
PLUS
metronidazole 400 mg orally, 12-hourly for 14 days metronidazole metronidazole metronidazole
PLUS EITHER
1doxycycline 100 mg orally, 12-hourly for 14 days doxycycline doxycycline doxycycline
OR for patients who are breastfeeding1 or likely to be nonadherent to doxycycline
2azithromycin 1 g orally, as a single dose, repeated 1 week later. azithromycin azithromycin azithromycin
For patients who have had a nonsevere (immediate or delayed) hypersensitivity reaction to a penicillin, use the regimen above.
For patients who have had a severe (immediate or delayed)2 hypersensitivity reaction to a penicillin, use metronidazole plus either doxycycline or azithromycin (as above). If Neisseria gonorrhoeae is identified, seek expert advice.
If the above regimens cannot be used and N. gonorrhoeae infection is excluded, considerBritish Association for Sexual Health and HIV (BASHH), 2019:
moxifloxacin 400 mg orally, daily for 14 days. For dosage adjustment in adults with kidney impairment, see moxifloxacin dosage adjustment. moxifloxacin moxifloxacin moxifloxacin
Assess the response to therapy within 72 hours and if the patient has not improved, review the diagnosis and consider switching to intravenous antibiotic therapy – see Empirical therapy for severe PID.
If Mycoplasma genitalium is detected, see PID caused by Mycoplasma genitalium.
If N. gonorrhoeae is identified, see Approach to Neisseria gonorrhoeae infection for information on additional testing (including test of cure) and contact tracing.
If C. trachomatis is identified, see Approach to Chlamydia trachomatis infection for information on additional testing (including test of cure) and contact tracing.
See also STI contact tracing.